Cochlear's Medicalization Push: A Patient Journey Reset

FY26 results show a deliberate shift from DTC alone to systematic referral networks, as Nexa adoption and margin pressures reshape the outlook.

COH.AX · Earnings Call · 2026-08-17

A Year of Two Pathways

Cochlear's FY26 results painted a picture of a company at an inflection point. Sales revenue grew just 2% in constant currency to $2.3 billion, and underlying net profit of $322 million landed at the upper end of April's revised guidance, but well short of the initial $400 million-plus target. The headline miss was driven by slower developed-market growth, particularly in the U.S. and Western Europe, where capacity constraints and insurance pushback took a toll. Yet CEO Dig Howitt's commentary suggested the more significant story is structural: Cochlear is rebalancing its growth engine away from a purely direct-to-consumer (DTC) model toward a professionally supported referral network. Howitt framed the challenge in terms of two distinct patient pathways: “There are broadly 2 ways in which candidates get to surgery... growth driven by actions we take to lead people to surgery, primarily through our direct-to-consumer activity. And there's an underlying level of market growth driven by aging population and increasing awareness.” — Dig Howitt, CEO and President · 2026-08-17 While Cochlear-supported DTC surgeries grew 10% in FY26, the so-called navigated pathway — where patients find their own way to clinics — actually declined. This separation is critical: it validates the company's investment in its own funnel, but exposes the fragility of organic market growth.

Medicalization as the Long-Term Fix

The strategic answer is medicalization — transforming hearing loss from a quality-of-life issue into a treatable medical condition with clear candidacy criteria and referral pathways. Howitt noted,

Our objective is to build a professionally supported referral program.
Dig Howitt, CEO and President · 2026-08-17

The company is already running pilots in four U.S. cities that engage ENTs who don't perform cochlear implant surgery, and plans to expand to twelve within six months. This echoes prior commentary from February 2026, when Howitt said, “We've been working hard in hearing aids on that. We are now doing more on the medical channel.” — Dig Howitt, CEO and President · 2026-02-13 The difference now is the systematic rollout and the clear link to the hearing loss therapy's long-term growth. Nexa, the new implant platform, is central to this evolution. It delivered an average 3% price increase and dominated developed-market sales within months, but it also contributed to a gross margin decline of 3 percentage points to 71%. CFO Sarah Thom explained that mix, manufacturing overhead absorption, and FX all played a role; she also emphasized that R&D spend rose 15% to 14% of sales, with investments in drug-eluting electrodes and a totally implantable device that could, as Howitt put it, “enable 24-hour hearing” — Dig Howitt, CEO and President · 2026-08-17. These products are expected to expand the market rather than cannibalize it.

FY27: A Bridge, Not a Break

Guidance for FY27 is cautious: low single-digit revenue growth and underlying net profit of $330–$350 million, with gross margin flat and operating expenses slightly down. The company has cut $40 million in annualized run-rate costs and reallocated $25 million into growth initiatives, but it is not banking on a rebound in underlying market growth. Instead, it is betting that the referral programs and Nexa's clinical benefits will compound over time, returning the company to its 18% NPAT margin target. As Howitt said in an earlier call, “We expect that we should be able to lift that up with the activity that we're undertaking.” — Diggory William Howitt, Chief Executive Officer and President · 2025-08-15 What changed at Cochlear is not the mission — it's the method. The company is no longer relying on patient pull alone; it's building a professional push. The question for investors is whether the patience required for medicalization will be rewarded before the margin drag and competitive pressure (Acoustics lost share) take a deeper toll. Investors are watching a deliberate, long-term pivot that could redefine how hearing loss is treated — and how Cochlear grows.